- Nycomed gets rights to NPS's Phase III Gattex; rights returned
- Nycomed takes on European rights to NPS's Preos; all rights later returned
- Amgen develops NPS Pharmaceuticals' calcium receptor tech.
- Follow-on nets $44.4mm for NPS Pharmaceuticals
- NPS Pharmaceuticals nets $53.3mm via FOPO
- NPS sells Regpara royalties to DRI Capital for $38.4mm
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.